Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain Amyloidosis.
Olivier F ClercSarah A M CuddyMichael Jerosch-HeroldDominik C BenzEthan KatznelsonJocelyn Canseco NeriAlexandra TaylorMarie Foley KijewskiGiada BianchiFrederick L RubergMarcelo F Di CarliRonglih LiaoRaymond Y KwongRodney H FalkSharmila DorbalaPublished in: medRxiv : the preprint server for health sciences (2023)
In AL amyloidosis, ECV detects subclinical cardiomyopathy. ECV tends to increase from baseline to 6 months and decreases significantly from 6 and 12 months of plasma cell therapy in AL-CMP. ECV provides excellent risk stratification and offers additional prognostic performance over Mayo AL stage.